125 related articles for article (PubMed ID: 35777022)
21. Usefulness of urinary calprotectin as a novel marker differentiating functional from structural acute kidney injury in the critical care setting.
John JS; Deepthi RV; Rebekah G; Prabhu SB; Ajitkumar P; Mathew G; Agarwal I
J Nephrol; 2023 Apr; 36(3):695-704. PubMed ID: 36809659
[TBL] [Abstract][Full Text] [Related]
22. Urinary biomarkers for the differentiation of prerenal and intrinsic pediatric acute kidney injury.
Westhoff JH; Fichtner A; Waldherr S; Pagonas N; Seibert FS; Babel N; Tönshoff B; Bauer F; Westhoff TH
Pediatr Nephrol; 2016 Dec; 31(12):2353-2363. PubMed ID: 27286687
[TBL] [Abstract][Full Text] [Related]
23. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
24. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis.
Saito Y; Sakamoto T; Kobayashi M; Takekuma Y; Higuchi I; Okamoto K; Sakakibara-Konishi J; Shimizu Y; Kinoshita I; Sugawara M
In Vivo; 2024; 38(2):800-806. PubMed ID: 38418143
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of renal function using cystatin C-based estimated glomerular filtration rate in patients with urothelial carcinoma treated with gemcitabine and cisplatin chemotherapy.
Nishimura F; Ushijima T; Hamada S; Kadowaki D; Miyamura S; Oniki K; Saruwatari J
J Clin Pharm Ther; 2021 Dec; 46(6):1622-1628. PubMed ID: 34339546
[TBL] [Abstract][Full Text] [Related]
27. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
Suppadungsuk S; Phitakwatchara W; Reungwetwattana T; Pathumarak A; Phakdeekitcharoen B; Kitiyakara C; Srisuwarn P; Davenport A; Nongnuch A
ESMO Open; 2022 Feb; 7(1):100351. PubMed ID: 34953401
[TBL] [Abstract][Full Text] [Related]
28. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Urinary Calprotectin, NGAL and KIM-1 in Chronic Kidney Disease.
Seibert FS; Sitz M; Passfall J; Haesner M; Laschinski P; Buhl M; Bauer F; Babel N; Pagonas N; Westhoff TH
Kidney Blood Press Res; 2018; 43(4):1255-1262. PubMed ID: 30078006
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
31. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
33. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
34. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
[TBL] [Abstract][Full Text] [Related]
36. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma.
Hosohata K; Washino S; Kubo T; Natsui S; Fujisaki A; Kurokawa S; Ando H; Fujimura A; Morita T
Toxicology; 2016 Jun; 359-360():71-5. PubMed ID: 27317936
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with
Khurana R; Deswal S; Prakash C; Singh DK
J Clin Diagn Res; 2016 Dec; 10(12):XC05-XC07. PubMed ID: 28208988
[TBL] [Abstract][Full Text] [Related]
38. Effect of combination sildenafil and gemfibrozil on cisplatin-induced nephrotoxicity; role of heme oxygenase-1.
Behiry S; Rabie A; Kora M; Ismail W; Sabry D; Zahran A
Ren Fail; 2018 Nov; 40(1):371-378. PubMed ID: 29707997
[TBL] [Abstract][Full Text] [Related]
39. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury.
Seibert FS; Pagonas N; Arndt R; Heller F; Dragun D; Persson P; Schmidt-Ott K; Zidek W; Westhoff TH
Acta Physiol (Oxf); 2013 Apr; 207(4):700-8. PubMed ID: 23336369
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Middleton G; Gridelli C; De Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Visseren-Grul CM; San Antonio B; John WJ; Zimmermann AH; Chouaki N; Paz-Ares L
Curr Med Res Opin; 2018 May; 34(5):865-871. PubMed ID: 29424248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
